Health and Pharma Morning Bulletin

Healthcare & Pharma Morning Bulletin

Results

Trading Statements / Contract Wins / Acquisitions:

ABCAM Plc  Year-end Trading Update

The Board has been pleased with the level of trading in the second half of the year, which has been strong despite the uncertainties in the global economic environment. Overall, sterling has been weaker than in the first half of the year and this has boosted sales more than was expected.

During the period we continued our policy of tight cost control both for cost of goods and other operating expenses. Together with the positive effect of exchange rates, this has contributed to higher gross margins, and allowed us to benefit from the operational gearing of the business. Overall this means that we anticipate that the profit before tax for the year will be around 9% ahead of current market consensus.

AGM & EGM:

Share Dealing:

Miscellaneous:

ReNeuron Group plc  Notification of Investor Evening

ValiRx PLC  HPV Test Starts Clinical Validation

GlaxoSmithKline PLC  Response to FDA Advisory Committees' Avandia vote

GlaxoSmithKline PLC  GSK Legal Update

Newspaper Investment Highlights:

Times – Need To Know

GlaxoSmithKline: The FTSE 100 drugs maker was told by the US Food and Drug Administration that Avandia, its diabetes treatment that is believed to raise the risk of heart attack, can stay on the US market, sending its shares up.

AstraZeneca: The FTSE 100 pharmaceuticals group said it will extend its research and development collaboration with Silence Therapeutics, the AIM-listed company, over its RNAi therapeutic molecules, which work on genes.